| Active substance | durvalumab |
| Holder | AstraZeneca n.v./s.a. |
| Status | closed |
| Indication | in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi® (durvalumab) as monotherapy adjuvant treatment after radical cystectomy for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 01/08/2025 |